Fellowship · New York, NY
Sponsored by Icahn School of Medicine at Mount Sinai
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
The New England journal of medicine · 2024 · 1,637 citations · Meena B Bansal
AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis.
Hepatology (Baltimore, Md.) · 2025 · 164 citations · Maria Fiel
AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis.
Hepatology (Baltimore, Md.) · 2025 · 138 citations · Maria Fiel
Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance.
Hepatology (Baltimore, Md.) · 2026 · 51 citations · Meena B Bansal
Pathogenesis of MASLD and MASH - role of insulin resistance and lipotoxicity.
Alimentary pharmacology & therapeutics · 2024 · 165 citations · Meena B Bansal
AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury.
Hepatology (Baltimore, Md.) · 2023 · 211 citations · Maria Fiel
Intratumoral dendritic cell-CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma.
Nature medicine · 2023 · 348 citations · Maria Fiel
Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study.
Journal of hepatology · 2021 · 397 citations · Costica Aloman, Ponni Perumalswami